Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Futura Medical convenes general meeting for 23 September

Following the announced capital raising, Futura Medical has sent a circular and convened a general meeting for 23 September 2026 at 10:00 at the offices of Panmure Liberum in London. The circular and the notice are available on the company website. Voting results on the resolutions will be published after the meeting via the RNS and on the website. » Plus sur de.investing.com
Futura Medical receives EU and UK approval for Eroxon Intense

Futura Medical has received marketing authorization for Eroxon Intense in the European Economic Area and the United Kingdom; certification was granted under CE conformity according to the EU Medical Device Regulation and the UKCA certification. Eroxon Intense is an improved, over‑the‑counter gel formulation for treating erectile dysfunction with faster and stronger sensory effects. Cooper Consumer Health has distribution rights in the EEA and UK; US approval by the FDA is expected in the second half of 2026, with a US launch planned for 2027 with partner MPG. In a user study of 223 men, about 70% of encounters reported satisfactory erection firmness and around 85% reported successful intercourse; more than half of participants said they were likely to purchase the product. » Plus sur de.investing.com
Futura Medical loses European patent for Eroxon, will appeal

The Opposition Division of the European Patent Office confirmed after an oral hearing the revocation of European patent EP 3934624B1 for MED3000 (marketed as Eroxon). Futura Medical said it will appeal the decision to the EPO’s Technical Board of Appeal; the proceedings are likely to take 18–24 months or longer and patent protection remains in force during the appeal. The company emphasizes that the decision does not affect existing licensing and distribution agreements, the continued marketing of Eroxon, or its ability to supply, and that other patents and pending applications (including the European divisional application for MED3000 and WSD4000) are not affected. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, FUTURA MEDICAL a réalisé un chiffre d'affaires de 1,89 M € et un bénéfice net de -1,38 M €

(EUR)	juin 2026	YoY
Chiffre d'affaires	1,89 M	-
Bénéfice brut	1,83 M	-
Bénéfice net	-1,38 M	-
EBITDA	-1,45 M	-

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	758,97 k €
Nombre d'actions	339,33 M
Plus haut/bas sur 52 semaines	0,15 € - 0,00112 €
Dividendes	Non
Bêta	0,00
Ratio P/E	-0,44
Ratio PEG	-0,01
Ratio P/B	0,81
Ratio P/S	0,41

Profil de l'entreprise

Futura Medical plc, ein pharmazeutisches Unternehmen, entwickelt pharmazeutische und Gesundheitsprodukte für den Gesundheitsmarkt mit Schwerpunkt auf sexueller Gesundheit und Schmerzlinderung. Sein Hauptprodukt ist MED3000, ein topisches Gel zur Behandlung von Erektionsstörungen. Das Unternehmen entwickelt auch Produkte zur Schmerzlinderung, darunter TPR100, ein topisches Diclofenac-Schmerzlinderungsgel, CBD100, eine topische Cannabidiol-Formulierung, und TIB200, ein topisches Ibuprofen-Schmerzlinderungsgel. Das Unternehmen wurde 2001 gegründet und hat seinen Hauptsitz in Guildford (Vereinigtes Königreich).